Gepotidacin

Gepotidacin
Sonraí cliniciúla
Grúpa cógaseolaíochta	comhdhúil cheimiceach
Sonraí ceimiceacha agus fisiceacha
Foirmle	C24H28N6O3
Mais mhóilíneach	448.222 Da
Aitheantóirí
Uimhir CAS	1075236-89-3
PubChem (SID)	25101874
IUPHAR/BPS	10817
DrugBank	DB12134
ChemSpider	34982930
UNII	DVF0PR037D
ChEMBL	CHEMBL3317856
PDB liogann ID	JHN
ECHA	100.249.088

Is cógas antaibheathach é gepotidacin, a dhíoltar faoin ainm branda Blujepa, a úsáidtear chun ionfhabhtú chonair an fhuail nó gónairith úraigineach neamhchasta a chóireáil.^[1]^[2] Is coscaire topaisiméaráise baictéarach triazaacenaphthiléin cineál II é gepotidacin.^[3] Úsáidtear é mar an salann gepotidacin mesylate, agus tógtar é tríd an mbéal.

Ceadaíodh Gepotidacin lena úsáid go míochaine sna Stáit Aontaithe i mí an Mhárta 2025.^[4]

Úsáidí leighis

Léirítear Gepotidacin le haghaidh cóireáil baineannaigh dhá bhliain déag d'aois agus níos sine, a bhfuil meáchan 40 cileagram ar a laghad acu, a bhfuil ionfhabhtú neamhchasta sna fual-chonairí (uUTI) orthu, de bharr Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii coimpléascach, Staphylococcus saprophyticus, agus Enterococcus faecalis.^[5]

I mí na Nollag 2025, leathnaíodh an tásc chun cóireáil a chur ar othair a bhfuil gónairith úraigineach neamhchasta orthu agus a bhfuil meáchan 99 pounds (45 kg) ar a laghad acu.^[2]

Tagairtí

↑ "Blujepa- gepotidacin tablet, film coated".
1 2 "FDA Approves Two Oral Therapies to Treat Gonorrhea". U.S. Food and Drug Administration (FDA) (Preaseisiúint). 12 December 2025. Aisghafa 13 December 2025. This article incorporates text from this source, which is sa fearann poiblí.
↑ "In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens" (January 2016). Antimicrobial Agents and Chemotherapy 60 (3): 1918–1923. doi:10.1128/aac.02820-15. PMID 26729499.
↑ "In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens" (January 2016). Antimicrobial Agents and Chemotherapy 60 (3): 1918–1923. doi:10.1128/aac.02820-15. PMID 26729499.
↑ Krewson (25 March 2025). “FDA approves gepotidacin for uncomplicated UTI treatment in females 12 years and up”. Contemporary Pediatrics. Dáta rochtana: 15 April 2025.

[Blujepa_FDA_label-1] "Blujepa- gepotidacin tablet, film coated".

[FDA_PR_20251212-2] 1 2 "FDA Approves Two Oral Therapies to Treat Gonorrhea". U.S. Food and Drug Administration (FDA) (Preaseisiúint). 12 December 2025. Aisghafa 13 December 2025. This article incorporates text from this source, which is sa fearann poiblí.

[3] "In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens" (January 2016). Antimicrobial Agents and Chemotherapy 60 (3): 1918–1923. doi:10.1128/aac.02820-15. PMID 26729499.

[4] "In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens" (January 2016). Antimicrobial Agents and Chemotherapy 60 (3): 1918–1923. doi:10.1128/aac.02820-15. PMID 26729499.

[Krewson_2025-5] Krewson (25 March 2025). “FDA approves gepotidacin for uncomplicated UTI treatment in females 12 years and up”. Contemporary Pediatrics. Dáta rochtana: 15 April 2025.

[1]

[2]

[3]

[4]

[5]